French research suggests benefit from chemo combination

[PCUK Nurse Jeni]

A French research study published in the New England Journal of Medicine has shown a survival benefit from a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) for patients with metastatic pancreatic cancer. Although this combination does cause more side effects.

For more information see http://www.latimes.com/health/boostershots/la-heb-pancreatic-cancer-drug-cocktail-05112011,0,2372897.story

or http://www.nejm.org/doi/full/10.1056/NEJMoa1011923